Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
InfuSystem Holdings Inc (INFU)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
$13.56+3.12%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.57 → 0.57 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for INFU yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA margin stays in mid to low 20%'s in 2026 | Profit margins stay in the mid to low 20% range. | Improving | Adjusted EBITDA margin falls below low 20% range in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “Meaningful Margin Expansion Underway • Infrastructure investments complete • Growth mix shifting toward less capital-intensive opportunities • Adjusted EBITDA margin of 21.9% for FY 2025 • Long-term target: 22%-25% 3.” “We also are continuing to forecast Adjusted EBITDA margin (non-GAAP) to be in the mid to low 20%'s.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
INFU is a small-cap growth business with a meaningful execution risk, rather than a proven, steady compounder. Its long-term thesis is intact, supported by recent strong results, but the company remains loss-making and the evidence window is limited.
Valuation is stretched, at a 7% premium to peers, while the expectations gap is aligned. That suggests expectations are broadly in line with the available valuation evidence, without a clear sign that the thesis is unusually fragile.
Near term, management’s 2026 revenue growth goal remains 6% to 8%; Patient Services revenue rose across the two reported quarters, while Device Solutions revenue fell year over year in both. Adjusted EBITDA margin improved from 18.9% to 23.4%, but full-year margin delivery remains mixed, and a guidance cut would be a meaningful risk. Recent earnings beats and the start of the share repurchase program add evidence of execution, though losses and small-cap miss risk remain relevant.
Over the next few quarters, the thesis depends on sustaining revenue growth and keeping margins near management’s stated range without a guidance cut. A weakening jobs trend could raise recession concerns for cyclical businesses, while continued strength from large Healthcare companies could support the sector backdrop.
For the next 1 to 3 years, INFU has improving execution and a stronger sector backdrop, but its loss-making profile, elevated risk, and stretched valuation leave the thesis dependent on continued delivery. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Revenue reaches at least $33.7 million in 2026 | A primary condition in InfuSystem Holdings Inc's published investment case. The stated target is >= $33.7 million. | Intact | Revenue falls below $33.7 million in FY26 | Revenue: $36.933M FY2026-Q2; GAAP. Published target: >= $33.7 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 4, 202636,933,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete $20 million stock repurchase program starting July 2026 | The company is buying back $20 million of stock, showing confidence. | Intact | Stock buyback program is not executed or is materially delayed | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.55 → $0.57 · observed estimates
$0.16B → $0.15B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-07-25 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-07-26 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-07-27 | $0.55 | $155,709,000 | 3 / 3 |
| 2026-07-28 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-07-29 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-07-30 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-07-31 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-08-01 | $0.55 | $155,709,000 | 3 / 3 |
| 2026-08-02 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-08-03 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-08-04 | $0.55 | $155,709,000 | 3 / 3 |
| 2026-08-05 | $0.55 | $155,709,000 | 4 / 4 |
| 2026-08-06 | $0.56 | $155,505,250 | 4 / 4 |
| 2026-08-07 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-08 | $0.56 | $155,505,250 | 4 / 4 |
| 2026-08-09 | $0.56 | $155,505,250 | 4 / 4 |
| 2026-08-10 | $0.56 | $155,505,250 | 4 / 4 |
| 2026-08-12 | $0.56 | $155,605,250 | 4 / 4 |
| 2026-08-13 | $0.56 | $155,605,250 | 4 / 4 |
| 2026-08-14 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-15 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-16 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-17 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-18 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-19 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-20 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-21 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-22 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-23 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-24 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-25 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-26 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-27 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-28 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-29 | $0.56 | $155,605,250 | 3 / 3 |
| 2026-08-30 | $0.57 | $154,107,000 | 3 / 3 |
| 2026-08-31 | $0.57 | $154,107,000 | 3 / 3 |
| 2026-09-01 | $0.57 | $154,107,000 | 3 / 3 |
| 2026-09-02 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-03 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-04 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-05 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-06 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-07 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-08 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-09 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-10 | $0.57 | $154,107,000 | 2 / 2 |
| 2026-09-11 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-12 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-13 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-14 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-15 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-16 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-17 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-18 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-19 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-20 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-21 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-22 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-23 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-24 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-25 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-26 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-27 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-28 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-29 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-09-30 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-01 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-02 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-03 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-04 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-05 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-06 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-07 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-08 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-09 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-10 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-11 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-12 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-13 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-14 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-15 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-16 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-17 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-18 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-19 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-20 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-21 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-22 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-23 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-24 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-25 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-26 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-27 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-28 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-29 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-30 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-10-31 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-11-01 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-11-02 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-11-03 | $0.57 | $154,107,000 | 1 / 2 |
| 2026-11-04 | $0.57 | $154,107,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.